Hanne Kuitunen

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Mats Jerkeman, Christian Winther Eskelund, Martin Hutchings et al. · The Lancet Haematology · 2018 · 145 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +7

Engraftment and outcome after autologous stem cell transplantation in plerixafor‐mobilized non‐<scp>H</scp>odgkin's lymphoma patients

Ville Varmavuo, Johanna Rimpiläinen, Hanne Kuitunen et al. · Transfusion · 2013 · 30 citations

Expression and prognostic evaluation of oxidative stress markers in an immunohistochemical study of B-cell derived lymphomas

Anna Kaisa Pasanen, Hanne Kuitunen, Kirsi‐Maria Haapasaari et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2011 · 26 citations

Lipid Peroxidation, Immunology, Pathology +26

Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL)

Hanne Kuitunen, Susanna Tokola, T Siniluoto et al. · Journal of Neuro-Oncology · 2016 · 26 citations

Neuro-oncology, Cell Therapy, Transplantation +12

Significance of bulky mass and residual tumor—Treated with or without consolidative radiotherapy—To the risk of relapse in DLBCL patients

Susanna Tokola, Hanne Kuitunen, Taina Turpeenniemi‐Hujanen et al. · Cancer Medicine · 2020 · 23 citations · Full text